CIK 0001662774 · Non-accelerated filer<br>Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 901024039
- Phone
- 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 70 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-04 | McLoughlin Margaret Director | Grant or award · Director Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2025-06-04 | Patni Rajiv Director | Grant or award · Director Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2025-06-04 | Bray June Director | Grant or award · Director Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2025-01-28 | Thye Dirk CEO AND CHIEF MEDICAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +1,200,000 | 1,200,000 | ||
| 2025-01-28 | Ryan Charles S. PRESIDENT | Grant or award · Employee Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2025-01-28 | Hannah Brendan CBO, COO and CCO | Grant or award · Employee Stock Option (right to buy) | +450,000 | 450,000 | ||
| 2025-01-02 | McLoughlin Margaret Director | Grant or award · Director Stock Option (right to buy) | +31,613 | 31,613 | ||
| 2025-01-02 | Bray June Director | Grant or award · Director Stock Option (right to buy) | +30,282 | 30,282 | ||
| 2025-01-02 | Lamond David Director | Grant or award · Director Stock Option (right to buy) | +47,587 | 47,587 | ||
| 2025-01-02 | Senner Christopher J. Director | Grant or award · Director Stock Option (right to buy) | +35,274 | 35,274 | ||
| 2024-10-23 | Benatti Luca Director | Other acquisition | +8,918 | 89,179 | ||
| 2024-08-30 | Thye Dirk CEO AND CHIEF MEDICAL OFFICER | Purchase | +77,000 | $0.70 | $54K | 843,941 |
| 2024-08-29 | Thye Dirk CEO AND CHIEF MEDICAL OFFICER | Purchase | +77,500 | $0.69 | $53K | 766,941 |
| 2024-08-21 | Hannah Brendan CHIEF BUSINESS OFFICER AND COO | Purchase | +2,280 | $0.61 | $1K | 267,975 |
| 2024-08-21 | Hannah Brendan CHIEF BUSINESS OFFICER AND COO | Purchase | +5,000 | $0.62 | $3K | 272,975 |
| 2024-08-21 | Hannah Brendan CHIEF BUSINESS OFFICER AND COO | Purchase | +23,565 | $0.63 | $15K | 296,540 |
| 2024-08-20 | Ryan Charles S. PRESIDENT | Purchase | +48,387 | $0.65 | $31K | 122,461 |
| 2024-08-20 | Hannah Brendan CHIEF BUSINESS OFFICER AND COO | Purchase | +2,500 | $0.61 | $2K | 262,271 |
| 2024-08-20 | Hannah Brendan CHIEF BUSINESS OFFICER AND COO | Purchase | +3,424 | $0.60 | $2K | 265,695 |
| 2024-08-19 | Hannah Brendan CHIEF BUSINESS OFFICER AND COO | Purchase | +2,155 | $0.58 | $1K | 259,771 |
Page 3 of 8 · 149 trades